CANNABIS SCIENCE WKN: A0RM6Z ISIN: US1376481016 Kürzel: CXN Forum: Aktien Thema: Hauptdiskussion

ok es fängt sich?!

Wie es steigt

Schön es steigt.

Moin! Bei den Amis is ja fett Umsatz die Tage! Ob sich da einige Leutchen schon positionieren? Schönen Sonntag allseits!

Als Prozessdatum habe ich den 15.6. notiert, aber ich finde die Quelle auch nicht mehr.

Sie wird aber vor dem steigen Schwung holen so nach 0,034 gehts dann rauf

langsam dürfte das steigen beginnen

in meinem Kopf ist irgendwie 7 oder 8. gespeichert wird aber falsch sein. finde es nicht

Wann geht es weiter mit dem Prozess ?

gegen den Staat wegen beschlagnahme ihres Feldes

Welchen Prozess?

Vonda das wollte ich auch fragen. Ist auch von heute morgen... kennt sich jemand aus...??

was bedeutet dies?

NT 10-Q 1 cbis-20170516_nt10q1.htm NT10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 000-28911 CUSIP NUMBER 137648101 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: PART I — REGISTRANT INFORMATION CANNABIS SCIENCE INC. Full Name of Registrant N/A Former Name if Applicable 19800 MacArthur Blvd., Suite #300 Address of Principal Executive Office (Street and Number) Irvine, California 92612 City, State and Zip Code 1 PART II — RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. PART III — NARRATIVE State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. The Registrant requires additional time to file its Form 10-Q so that it can complete the necessary review and compilation of information to file a complete and accurate report. PART IV — OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification Raymond C. Dabney (888) 889-0888 (Name) (Area Code) (Telephone Number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [ X ] Yes [ ] No (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [ X ] No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. 2 CANNABIS SCIENCE, INC. (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 16, 2017 By: /s/ Raymond C. Dabney Raymond C. Dabney Title: President & Chief Executive Officer 3

Mit Sicherheit...:-) Danke Vonda...

das word sicherlich medientechnisch benutzt und sich auch auf den Prozess auswirken.